Q3 2025 · 13F-HR
SR ONE CAPITAL MANAGEMENT, LPholdings as filed
Filed 2025-11-12 · accession 0001193125-25-277769
$691.4M
Reported value
12
Positions
2025-09-30
Period end
The Brief · SR ONE CAPITAL MANAGEMENT, LP · Q3 2025
AI · grounded in 13F
SR ONE CAPITAL MANAGEMENT, LP established a new position in Arcellx, Inc. ACLXGBX valued at $192.7M. The fund also initiated new stakes in CRISPR Therapeutics AG CRSP for $132.1M and Zenas BioPharma, Inc ZBIO for $109M. Additional new positions include Mineralys Therapeutics Inc. MLYS, ORIC Pharmaceuticals, Inc. ORIC, and Design Therapeutics, Inc. DSGN.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 03940C100 | ACLXGBX | Arcellx, Inc. | $192.7M | 27.9% | 2,346,630 | Common | SOLE |
| H17182108 | CRSP | CRISPR Therapeutics AG | $132.1M | 19.1% | 2,038,763 | Common | SOLE |
| 98937L105 | ZBIO | Zenas BioPharma, Inc | $109.0M | 15.8% | 4,911,539 | Common | SOLE |
| 603170101 | MLYS | Mineralys Therapeutics Inc. | $80.2M | 11.6% | 2,113,933 | Common | SOLE |
| 68622P109 | ORIC | ORIC Pharmaceuticals, Inc. | $54.2M | 7.84% | 4,514,929 | Common | SOLE |
| 25056L103 | DSGN | Design Therapeutics, Inc. | $49.1M | 7.11% | 6,526,476 | Common | SOLE |
| 82835W108 | SPRY | ARS Pharmaceuticals, Inc. | $40.3M | 5.83% | 4,012,903 | Common | SOLE |
| 687604108 | ORKA | Oruka Therapeutics, Inc | $8.3M | 1.20% | 430,330 | Common | SOLE |
| 022307102 | ALMS | Alumis Inc. | $7.8M | 1.13% | 1,959,896 | Common | SOLE |
| 65487U108 | NKTX | Nkarta, Inc. | $6.9M | 1.00% | 3,333,333 | Common | SOLE |
| H5870P102 | OCS | Oculis Holding AG | $5.7M | 0.82% | 322,500 | Common | SOLE |
| 29286M105 | — | enGene Holdings Inc. | $5.1M | 0.74% | 747,750 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.